Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.

Melo-González F, Soto JA, González LA, Fernández J, Duarte LF, Schultz BM, Gálvez NMS, Pacheco GA, Ríos M, Vázquez Y, Rivera-Pérez D, Moreno-Tapia D, Iturriaga C, Vallejos OP, Berríos-Rojas RV, Hoppe-Elsholz G, Urzúa M, Bruneau N, Fasce RA, Mora J, Grifoni A, Sette A, Weiskopf D, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Ramírez E, Kalergis AM, Bueno SM.
Melo-González F, et al.
Front Immunol. 2021 Nov 9;12:747830. doi: 10.3389/fimmu.2021.747830. eCollection 2021.
Front Immunol. 2021.

PMID: 34858404
Free PMC article.


Clinical Trial.

NOW WITH OVER +8500 USERS. people can Join Knowasiak for free. Sign up on
Read More


1 Comment

  1. Can’t access the article, but a few things make me skeptical.

    They say micromolar (uM) affinity. That is usually not good enough. 10 uM is about the cutoff of what you would want in a lead compound – something to be further improved by a medicinal chemist. I suspect they were above 10 uM because if you have low uM affinity you should definitely call it out.

    They used a pseudo virus but do not say which. They do not tell you which cell line or cell type they used for their disease model. This info should have gone in the abstract. It would not have taken more than a few characters.

    Basically the quality of the abstract makes me doubt the quality of the research.

    Also please keep in mind that this is a pseudo virus in a cell model. The graveyard of drugs is filled with filled with compounds that looked good in disease models, but did not work. Generally, the further away you are from a live virus in a live human, the less predictive the model.